Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:169
Name neuroendocrine tumor
Definition An endocrine gland cancer that has_material_basis_in neuroendocrine cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer neuroendocrine tumor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
RB1 loss Sirolimus neuroendocrine tumor sensitive detail...
CDKN2A loss ZK 304709 neuroendocrine tumor sensitive detail...
BRAF V600E Dabrafenib + Trametinib neuroendocrine tumor sensitive detail...
BRAF V600E Trametinib + Vemurafenib neuroendocrine tumor predicted - sensitive detail...
MDM2 amp Milademetan neuroendocrine tumor predicted - sensitive detail...
CD274 positive Pembrolizumab neuroendocrine tumor predicted - sensitive detail...
MLH1 negative Pembrolizumab neuroendocrine tumor sensitive detail...
PMS2 negative Pembrolizumab neuroendocrine tumor sensitive detail...
MSH2 negative Pembrolizumab neuroendocrine tumor sensitive detail...
MSH6 negative Pembrolizumab neuroendocrine tumor sensitive detail...
RET fusion Selpercatinib neuroendocrine tumor sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00926640 Phase I Belinostat + Cisplatin + Etoposide A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers Completed USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA | GBR | FRA | ESP 0
NCT01466036 Phase II Cabozantinib Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Completed USA 0
NCT01841736 Phase II Pazopanib Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting USA | CAN 0
NCT02063958 Phase I SNX-5422 Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors Completed USA 0
NCT02205515 Phase Ib/II Everolimus An Open Label, Single-Centre, Phase II Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis Completed CAN 0
NCT02250885 Phase II Selinexor KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed USA 0
NCT02259725 Phase II Regorafenib Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Completed USA 0
NCT02279433 Phase I Taletrectinib A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Completed USA 0
NCT02315625 Phase II Everolimus Sunitinib Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery Terminated USA 0
NCT02399215 Phase II Nintedanib Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Completed USA 0
NCT02402920 Phase I Carboplatin + Etoposide + Pembrolizumab Cisplatin Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer Active, not recruiting USA 0
NCT02420691 Phase II Ribociclib LEE011 in Neuroendocrine Tumors of Foregut Origin Completed USA 0
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | DEU | BEL 2
NCT02487095 Phase Ib/II Berzosertib Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Active, not recruiting USA 0
NCT02489903 Phase II Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens Completed USA 0
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 16
NCT02754297 Phase II lutetium Lu 177 dotatate Personalized PRRT of Neuroendocrine Tumors (P-PRRT) Recruiting CAN 0
NCT02795858 Phase II Octreotide + Ramucirumab A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Active, not recruiting USA 0
NCT02831179 Phase I Capecitabine + Temozolomide + Veliparib Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn 0
NCT02875223 Phase I CC-90011 A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas Active, not recruiting ITA | GBR | FRA | ESP 1
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA | GBR 0
NCT02939651 Phase II Pembrolizumab A Study of Pembrolizumab in Patients With Neuroendocrine Tumors Completed USA 0
NCT02955069 Phase II Spartalizumab Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 2
NCT03014297 Phase I Everolimus + Fosbretabulin Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression Terminated USA 0
NCT03034200 Phase II ONC201 Phase 2 Study of ONC201 in Neuroendocrine Tumors Completed USA 0
NCT03070301 Phase II Everolimus + Ribociclib A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors Completed USA 0
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Active, not recruiting USA 0
NCT03095274 Phase II Durvalumab Tremelimumab Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) Completed ESP 0
NCT03211988 Phase II Entinostat Entinostat Neuroendocrine (NE) Tumor Terminated USA 0
NCT03289741 FDA approved Lanreotide acetate + Octreotide A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Completed USA 0
NCT03290079 Phase II Pembrolizumab Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas Active, not recruiting USA 0
NCT03365791 Phase II Ieramilimab Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03375320 Phase III Cabozantinib Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03411915 Phase I XmAb18087 A Study of XmAb18087 in Subjects With NET and GIST Completed USA 0
NCT03420521 Phase II Ipilimumab + Nivolumab Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Terminated USA 0
NCT03457948 Phase II Pembrolizumab Pembrolizumab + Yttrium-90 microsphere therapy Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases Active, not recruiting USA 0
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03950609 Phase II Everolimus + Lenvatinib Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors Active, not recruiting USA 0
NCT03980925 Phase II Carboplatin + Etoposide + Nivolumab Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Active, not recruiting ESP 0
NCT04197310 Phase II Cabozantinib + Nivolumab Cabozantinib and Nivolumab for Carcinoid Tumors Completed USA 0
NCT04234568 Phase I lutetium Lu 177 dotatate + Triapine Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors Active, not recruiting USA 0
NCT04400474 Phase II Atezolizumab + Cabozantinib Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) Active, not recruiting ESP 0
NCT04412629 Phase II Cabozantinib Cabozantinib in High Grade Neuroendocrine Neoplasms Recruiting USA 0
NCT04427787 Phase II Cabozantinib + Lanreotide acetate A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) Unknown status ITA 0
NCT04450901 Phase I YBL-006 Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors Active, not recruiting AUS 2
NCT04471727 Phase Ib/II Atezolizumab + HPN328 HPN328 Study in Patients With Advanced Cancers Associated With Expression of DLL3 Recruiting USA 0
NCT04524208 Phase II Cabozantinib A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 (CABONEN) Recruiting DEU 0
NCT04525638 Phase II lutetium Lu 177 dotatate + Nivolumab A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours Recruiting ESP 0
NCT04579679 Phase II Surufatinib Open-Label Surufatinib in European Patients With NET Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 1
NCT04579757 Phase Ib/II Surufatinib + Tislelizumab Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04614766 Phase Ib/II 131I-MIBG + lutetium Lu 177 dotatate lutetium Lu 177 dotatate A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3) Recruiting USA 0
NCT04750954 Phase I lutetium Lu 177 dotatate + Peposertib Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors Active, not recruiting USA 0
NCT04776876 Phase II Retifanlimab + Telotristat etiprate Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome Withdrawn 0
NCT04802174 Phase Ib/II Berzosertib + Lurbinectedin A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers Recruiting USA 0
NCT04814732 Expanded access Surufatinib Expanded Access Program of Surufatinib No longer available USA 0
NCT05000294 Phase Ib/II Atezolizumab + Tivozanib Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Recruiting USA 0
NCT05178693 Phase I Decitabine and Cedazuridine + lutetium Lu 177 dotatate Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana) Recruiting GBR 0
NCT05268666 Phase Ib/II JBI-802 A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05289856 Phase II Avelumab + Cabozantinib Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3) Active, not recruiting DEU 0
NCT05420636 Phase II ORY-1001 + Paclitaxel Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Recruiting USA 0
NCT05546268 Phase Ib/II MRT-2359 Study of Oral MRT-2359 in Selected Cancer Patients Recruiting USA | CAN 0
NCT05554003 Phase II Temozolomide Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study (MeTe) Recruiting ITA 0
NCT05619744 Phase I RO7616789 A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas Recruiting USA 2
NCT05636618 Phase Ib/II [212Pb]VMT01 Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT) Recruiting USA 0
NCT05691491 Phase Ib/II M1774 + Temozolomide Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness Recruiting USA 0
NCT05724108 Phase II lutetium Lu 177 dotatate lutetium Lu 177 dotatate + Triapine Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors Recruiting USA 0
NCT05746208 Phase II Lenvatinib + Pembrolizumab Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors Recruiting USA 0
NCT05773274 Phase Ib/II Everolimus lutetium Lu 177 dotatate Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial Recruiting USA | CAN 0
NCT05870423 Phase I lutetium Lu 177 dotatate + Olaparib Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors (PRRT-PARPi) Recruiting 1
NCT05918302 Phase III 177Lu-edotreotide Everolimus Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (LEVEL) Recruiting ITA | FRA | ESP 0
NCT06041516 Phase I ADCT-701 Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas Not yet recruiting USA 0
NCT06148636 Phase I 212Pb-VMT-alpha-NET A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors Recruiting USA 0